An Introduction to Providing Rehabilitation to Individuals who Have Been Implanted with the Argus II Retinal Prosthesis System

Berson E. L. , Rosner B. , Weigel-DiFranco C. , Dryja T. P. , & Sandberg M. A. (2002). Disease progression in patients with dominant retinitis pigmentosa and rhodopsin mutations. Investigative Ophthalmology & Visual Science, 43, 3027–3036.

da Cruz L. , Dorn J. D. , Humayun M. S. , Dagnelie G. , Handam J. , Baralem P. O. , … Greenberg R. J. (2016). Five-year safety and performance results from the Argus II Retinal Prosthesis System clinical trial. Ophthalmology, 23(10), 2248–2254.

Geruschat D. R. , & Dagnelie G. (2016). Restoration of vision following long-term blindness: Considerations for providing rehabilitation. Journal of Visual Impairment & Blindness, 110(1), 5–13.

Ho A. C. , Humayun M. S. , Dorn J. D. , da Cruz L. , Dagnelie G. , Handa J. , … Green-berg R. J. (2015). Long-term results from an epiretinal prosthesis to restore sight to the blind. Ophthalmology, 122(8), 1547–1554.

Mead B. , Berry M. , Logan A. , Scott R. , Lead-beater W. , & Scheven B. (2015). Stem cell treatment of degenerative eye disease. Stem Cell Research 14(3), 243–257.

Petit L. , Khanna H. , & Punzo C. (2016). Advances in gene therapy for diseases of the eye. Human Gene Therapy 27(8), 563–579.

Spark Therapeutics. (2017). Safety and efficacy study in subjects with Leber Congenital Amaurosis, NCT00999609 (Clinical trial). Retrieved from https://clinicaltrials.gov/ct2/show/NCT00999609